Although there is currently no nasal vaccine being tested in India, the Serum Institute of India in Pune and Bharat Biotech in Hyderabad will soon begin clinical trials of intranasal Covid-19 vaccines, said the Union’s health minister, the Dr. Harsh Vardhan.
Bharat Biotech, which is developing a native vaccine in collaboration with the Indian Council for Medical Research, has reached an agreement with Washington University and St. Louis University for trials of the nasal vaccine candidate.
The Serum Institute of India, which is conducting the phase 2/3 clinical trial of the Oxford-Astrazeneca vaccine, has an agreement with Codagenix for its nasal vaccine.
Nasal vaccines are injections that can be administered through the nose, so they do not require a doctor or nurse to administer.
Responding to a question about the inclusion of the vaccines currently being tested, Harsh Vardhan said that participants in the vaccine trial also include the young and the elderly. The Serum Institute Phase 3 trial includes people up to 99 years old. The lowest age limit is 12 years for most ongoing trials, the minister said.
One day later, Dr. Reddy obtained approval for the Russian Sputnik V clinical trial, it became known that Mankind Pharma has collaborated with the Russia Direct Investment Fund for the sale and distribution of Sputnik V in India.
.
